CIK 0001374339 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
ProMIS Neurosciences Inc.
Sign in to watch- Ticker
- PMN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- 416-847-6898
- Business address
- SUITE 200, 1920 YONGE STREET, TORONTO, Ontario, Canada, M4S 3E2
- Former names
- AMORFIX LIFE SCIENCES LTD
- Open-market buys, last 90 days
- $134,746
- in 3 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$134,746. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-04 | Williams Eugene Director | Purchase | +26,500 | $3.43 | $91K | 40,213 |
| 2026-11-02 | Cashman Neil Chief Scientific Officer | Purchase | +10,000 | $3.86 | $39K | 14,532 |
| 2026-10-30 | Williams Eugene Director | Purchase | +1,316 | $3.99 | $5K | 13,713 |
| 2026-10-05 | Rubino Ivana Chief Commercial Officer | Grant or award · Option (right to buy) | +80,000 | 80,000 | ||
| 2026-08-05 | Kaplan Johanne Chief Development Officer | Purchase | +2,280 | $13.30 | $30K | 6,221 |
| 2026-05-20 | WYMAN WILLIAM W Director | Grant or award · Option (right to buy) | +5,500 | 5,500 | ||
| 2026-05-20 | WYMAN WILLIAM W Director | Grant or award · Option (right to buy) | +11,000 | 11,000 | ||
| 2026-05-20 | Williams Eugene Director | Grant or award · Option (right to buy) | +5,500 | 5,500 | ||
| 2026-05-20 | Williams Eugene Director | Grant or award · Option (right to buy) | +11,000 | 11,000 | ||
| 2026-05-20 | Warma Neil K Chief Executive Officer | Grant or award · Option (right to buy) | +160,000 | 160,000 | ||
| 2026-05-20 | Shafmaster Madge K. Director | Grant or award · Option (right to buy) | +5,500 | 5,500 | ||
| 2026-05-20 | Shafmaster Madge K. Director | Grant or award · Option (right to buy) | +11,000 | 11,000 | ||
| 2026-05-20 | Cashman Neil Chief Scientific Officer | Grant or award · Option (right to buy) | +50,000 | 50,000 | ||
| 2026-05-20 | Milbury Max A. Principal Accounting Officer | Grant or award · Option (right to buy) | +18,167 | 18,167 | ||
| 2026-05-20 | Mandel-Brehm Josh Director | Grant or award · Option (right to buy) | +5,500 | 5,500 | ||
| 2026-05-20 | Mandel-Brehm Josh Director | Grant or award · Option (right to buy) | +11,000 | 11,000 | ||
| 2026-05-20 | Kaplan Johanne Chief Development Officer | Grant or award · Option (right to buy) | +50,000 | 50,000 | ||
| 2026-05-20 | Alex Slanix Paul Director | Grant or award · Option (right to buy) | +5,500 | 5,500 | ||
| 2026-05-20 | Alex Slanix Paul Director | Grant or award · Option (right to buy) | +11,000 | 11,000 | ||
| 2026-04-22 | Kirwin Patrick D. Director | Purchase | +4,000 | $11.33 | $45K | 4,653 |
Page 1 of 8 · 158 trades